Healthcare
FNArena Windows (Sectors)
Introduction to FNArena Windows
FNArena Windows offers subscribers the option to investigate ASX-listed stocks against their peers. FNArena developed its own sector methodology which in our view overcomes many flaws and disadvantages connected with GICS sectors. Our system starts with three broad sector labels: COMMODITIES, FINANCIAL SERVICES and INDUSTRIALS. From here onwards subscribers can explore further through gradually narrowing branches. This is not investment advice, but simply another window on the Australian Stock Exchange to provide better insight and to assist FNArena subscribers while conducting their own market analysis.
Latest Stories
CSL’s FY26 result and FY27 guidance suggest a recovery may be underway following a long run of downgrades
Aug 19 2026
The FNArena Editor shares his views on investing, AI, Australian shares and about what to expect from the August results season
Aug 13 2026
| ASX CODE | COMPANY NAME | LAST PRICE | 52WK HIGH | 52WK LOW | P/E | CONSENSUS TARGET |
|---|---|---|---|---|---|---|
| 4DX | $3.48 | $7.55 | $1.40 | $4.50 | ||
| ACL | AUSTRALIAN CLINICAL LABS LIMITED | $2.76 | $3.03 | $1.83 | 14.8 | $2.65 |
| ALC | $0.11 | $0.14 | $0.08 | $0.15 | ||
| ARX | AROA BIOSURGERY LIMITED | $0.54 | $0.80 | $0.50 | 36.2 | $0.94 |
| AVH | AVITA MEDICAL INC | $2.78 | $3.08 | $1.00 | $2.95 | |
| AYA | $3.25 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| BB1 | $0.73 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| BIO | $0.37 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| CAT | CATAPULT SPORTS LIMITED | $3.01 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CGS | $3.01 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| COH | COCHLEAR LIMITED | $137.58 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CSL | CSL LIMITED | $169.50 | $xx.xx | $xx.xx | xx.x | xx.xx |
| CU6 | $2.24 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| CUV | $8.01 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| CYC | CYCLOPHARM LIMITED | $0.49 | $xx.xx | $xx.xx | xx.x | xx.xx |
| DOC | DOCTOR CARE ANYWHERE GROUP PLC | $0.13 | $xx.xx | $xx.xx | xx.x | xx.xx |
| EBO | EBOS GROUP LIMITED | $16.26 | $xx.xx | $xx.xx | xx.x | xx.xx |
| EBR | EBR SYSTEMS INC | $0.28 | $xx.xx | $xx.xx | xx.x | xx.xx |
| EGH | EUREKA GROUP HOLDINGS LIMITED | $0.64 | $xx.xx | $xx.xx | xx.x | xx.xx |
| EIQ | $0.57 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| EMV | $1.75 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| FPH | FISHER & PAYKEL HEALTHCARE CORPORATION LIMITED | $35.28 | $xx.xx | $xx.xx | xx.x | xx.xx |
| GSS | GENETIC SIGNATURES LIMITED | $0.08 | $xx.xx | $xx.xx | xx.x | xx.xx |
| HLS | HEALIUS LIMITED | $0.43 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IDX | INTEGRAL DIAGNOSTICS LIMITED | $2.29 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IME | IMEXHS LIMITED | $0.33 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMM | IMMUTEP LIMITED | $0.04 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMR | IMRICOR MEDICAL SYSTEMS INC | $1.81 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IMU | $0.06 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| INA | INGENIA COMMUNITIES GROUP | $3.85 | $xx.xx | $xx.xx | xx.x | xx.xx |
| IPD | IMPEDIMED LIMITED | $0.01 | $xx.xx | $xx.xx | xx.x | xx.xx |
| LDX | LUMOS DIAGNOSTICS HOLDINGS LIMITED | $0.10 | $xx.xx | $xx.xx | xx.x | xx.xx |
| LIC | LIFESTYLE COMMUNITIES LIMITED | $4.73 | $xx.xx | $xx.xx | xx.x | xx.xx |
| M7T | MACH7 TECHNOLOGIES LIMITED | $0.26 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MAP | $0.06 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| MPL | MEDIBANK PRIVATE LIMITED | $4.56 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MSB | MESOBLAST LIMITED | $2.17 | $xx.xx | $xx.xx | xx.x | xx.xx |
| MVF | $0.81 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| MVP | $0.51 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| MX1 | MICRO-X LIMITED | $0.02 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NAN | $2.75 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| NEU | NEUREN PHARMACEUTICALS LIMITED | $20.21 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NHF | NIB HOLDINGS LIMITED | $6.45 | $xx.xx | $xx.xx | xx.x | xx.xx |
| NUZ | $0.08 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| OCA | OCEANIA HEALTHCARE LIMITED | $0.61 | $xx.xx | $xx.xx | xx.x | xx.xx |
| OCC | ORTHOCELL LIMITED | $0.73 | $xx.xx | $xx.xx | xx.x | xx.xx |
| ONE | ONEVIEW HEALTHCARE PLC | $0.17 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PAR | $0.29 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| PGC | PARAGON CARE LIMITED | $0.14 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PME | $166.87 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| PNV | POLYNOVO LIMITED | $1.00 | $xx.xx | $xx.xx | xx.x | xx.xx |
| PYC | PYC THERAPEUTICS LIMITED | $2.32 | $xx.xx | $xx.xx | xx.x | xx.xx |
| REG | $4.56 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| RHC | RAMSAY HEALTH CARE LIMITED | $53.70 | $xx.xx | $xx.xx | xx.x | xx.xx |
| RMD | RESMED INC | $30.30 | $xx.xx | $xx.xx | xx.x | xx.xx |
| RYM | RYMAN HEALTHCARE LIMITED | $1.58 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SHL | SONIC HEALTHCARE LIMITED | $19.37 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SLD | $0.40 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| SNT | $0.02 | $xx.xx | $xx.xx | xx.x | xx.xx | |
| SNZ | SUMMERSET GROUP HOLDINGS LIMITED | $6.75 | $xx.xx | $xx.xx | xx.x | xx.xx |
| SOM | SOMNOMED LIMITED | $0.34 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TLX | TELIX PHARMACEUTICALS LIMITED | $16.76 | $xx.xx | $xx.xx | xx.x | xx.xx |
| TRJ | $0.16 | $xx.xx | $xx.xx | xx.x | xx.xx |
Previous Stories
Strong Result, Can Telix Continue To Deliver?
Jul 22 2026
Telix has continued to outperform operationally in 2026, but future upside is increasingly dependent on pipeline execution, regulatory approvals and therapeutic progress.
Treasure Chest: Beware Aussie Healthcare
Jul 17 2026
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is Australian healthcare stocks
Are Headwinds Building For ResMed In FY27?
Jul 14 2026
While one broker has turned more cautious on ResMed due to a one-off cost and risk of rising competition, analysts broadly welcome the MatrixCare sale as a strategic refocus backed by a sizeable shareholder return
A Technical Breakout For ResMed
Jul 07 2026
ResMed appears to have formed a technical bottom after breaking above key resistance, Fairmont Equities’ Michael Gable reports
Awaiting Catapult Sports’ Fundamental Re-Rating
Jun 15 2026
Following a stand-out FY26, analysts believe Catapult Sports’ execution and growth trajectory suggest a re-rating should follow
Treasure Chest: Pro Medicus
Jun 04 2026
FNArena’s Treasure Chest reports on money making ideas from stockbrokers and other experts. Today’s idea is Pro Medicus
Major UK Win Highlights Alcidion’s Potential
May 27 2026
Alcidion is accelerating growth through UK contract wins, recurring revenue expansion and the acquisition of Kyra Patient Flow in A&NZ
CSL Challenges Pile On, Where’s The Upside?
May 13 2026
CSL surprised even the most cautious commentators with (yet again) a hefty downgrade for future earnings. Analysts are questioning where to now?
Cochlear’s Shock Downgrade Raises Concerns
Apr 23 2026
Cochlear’s shock downgrade has challenged the long-held assumption the company is immune to economic cycles
The Biotech ‘Industrialisation’
Apr 20 2026
Australian biotechs are successfully turning promising science into a scalable, repeatable, commercial system. This ‘industrialisation’ can be highly beneficial for shareholders
Latest News
| 1 | The Market In Numbers – 12 Sep 2026Sep 12 2026 - Australia |
| 2 | ASX Winners And Losers Of Today – 11-09-26Sep 11 2026 - Daily Market Reports |
| 3 | Next Week At A Glance – 14-18 Sep 2026Sep 11 2026 - Weekly Reports |
| 4 | Objective Corp’s Turnaround ChallengeSep 11 2026 - Small Caps |
| 5 | Weekly Top Ten News Stories – 11 September 2026Sep 11 2026 - Weekly Reports |